Redeye judges that FluoGuide’s recently released progress update mostly confirms our expectations. Most importantly, the company remains on track to submit an IND application for registrational HGG trials and present interim data from its phase II HNC trial in H2 2025e. While additional partnership announcements and phase II meningioma/LGG data are slightly delayed, our investment thesis remains essentially unchanged.
LÄS MER
